Symbiosis C.M. Overview
Symbiosis C.M. is an innovative medical device company dedicated to solving anatomical variability in valvular heart disease, allowing better fit and better performance for existing medical devices, as well as standalone products for anatomies with great inter-patient variability. Symbiosis first product is ValSync, the first minimally invasive personalized solution for valve replacement.
Cumulative Funding Raised Over Time ($)
—Dec 2023
—Feb 2022
—Feb 2025
Latest News
growth-positive
The Next Generation of Heart Valves
The article discusses Dr. Shira Burg, a veterinarian who has developed a dynamic heart valve capable of changing shape during catheterization. This innovation could significantly benefit cardiac patients worldwide. Dr. Burg recently won a prestigious award at a leading cardiology conference, highlighting the potential impact of her work. She plans to conduct clinical trials in humans by 2027, marking a significant step forward in the development of this technology.
Product Stage
growth-positive
Symbiosis Wins TCT 2024 Shark Tank Innovation Competition
Symbiosis has won the TCT 2024 Shark Tank Innovation Competition for its adjustable transcatheter mitral valve replacement (TMVR) system, ValSync. The competition was held during the Transcatheter Cardiovascular Therapeutics symposium in Washington, DC. ValSync is designed to adapt to complex anatomies, offering potential benefits such as wider patient eligibility and superior safety. Symbiosis is currently in preclinical studies and plans to begin human testing in 2026. The company received a $200,000 award from the Jon DeHaan Foundation, which supports advancements in cardiac medicine. The recognition highlights Symbiosis innovation and potential to disrupt the cardiovascular field.
Product StageInvestment
growth-positive
Symbiosis Welcomes Prof. Marc Gillinov to Advisory Board
Symbiosis has announced the addition of Dr. Marc Gillinov to its Advisory Board. Dr. Gillinov is a renowned expert in mitral valve repair and robotic mitral valve surgery, currently serving as the Chair of the Department of Thoracic and Cardiovascular Surgery at Cleveland Clinic. His extensive experience and contributions to the field, including over 500 publications and educational videos, are expected to bring significant expertise to Symbiosis. This move is seen as a positive development for Symbiosis, potentially enhancing its capabilities and reputation in the cardiovascular domain.
growth-positive
Robert Schwartz Interviews Dr. Shira Burg at TCT Shark Tank 2024
Shira Burg, the Founder and CEO of Symbiosis, was awarded the Jon DeHaan Award at the TCT Shark Tank 2024. The interview highlights Shiras transition from veterinary medicine to human cardiology, emphasizing her dedication to treating structural heart disease. This recognition at a prestigious event like TCT Shark Tank is a significant milestone for Symbiosis, indicating a positive impact on the companys reputation and potential growth in the cardiology field.
growth-positive
ValSync Development Featured in JACC
The article discusses the ValSync device, a next-generation solution for Transcatheter Mitral Valve Replacement (TMVR), co-authored by Dr. Shira Burg and Dr. Yulia Cladco in JACC: Basic to Translational Science. ValSync addresses challenges in TMVR caused by irregular anatomy and mitral annular calcifications. Its design features inflatable balloons that adapt to individual patient anatomy, providing stability and reducing risks such as paravalvular leaks and left ventricular outflow tract obstruction. This innovation could broaden patient eligibility and simplify the TMVR procedure. Initial animal trials have shown promising results, with potential first-in-human trials expected in 2026.
Product Stage
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | Undisclosed |
| Last funding | Undisclosed |
| Stage | Seed |
| Rounds | 5 |
| Investors | 0 |
Team Members
4
Employees: 11-50
Web & Social Links
| Website | symbiosis-cm.com/ |
Locations
Ha-Sivim St 18, Petah Tikva, Israel
Photos & Videos
No files yet
Symbiosis C.M. Business
Business models
B2B
Product stage
R&D
Employees
11-50
Sector
Health Tech & Life SciencesMedical DevicesMedical Treatment & TherapeuticsTarget Customer
Healthcare & Life SciencesMedical Devices IndustryCore Technology
Materials & SubstancesPolymersComponentsModularTags (5)
valvescardiologyminimally-invasivemedical-devicesheart-diseasesGeographic Markets
EuropeNorth AmericaSymbiosis C.M. Financials
Undisclosed
Total funding
Undisclosed
Capital raised
Undisclosed
Last funding
Seed
Funding stage
5
Total rounds
0
Investors
Cumulative Funding Raised Over Time ($)
—Dec 2023
—Feb 2022
—Feb 2025
Private Equity Funding
Seed
Feb 2025
Undisclosed
Seed
Dec 2023
Undisclosed
Pre-Seed
Feb 2022
Undisclosed
Non-Equity Funding
GrantEvent
Dec 2024
Undisclosed
GrantEvent
May 2023
Undisclosed
Symbiosis C.M. Lifecycle
Cumulative Funding Raised Over Time
—Dec 2023
—Feb 2022
—Feb 2025
All Events
Seed
Feb 2025
Undisclosed
Seed
Dec 2023
Undisclosed
Pre-Seed
Feb 2022
Undisclosed
GrantEvent
Dec 2024
Undisclosed
GrantEvent
May 2023
Undisclosed
Symbiosis C.M. News
10 articles
growth-positive
The Next Generation of Heart Valves
The article discusses Dr. Shira Burg, a veterinarian who has developed a dynamic heart valve capable of changing shape during catheterization. This innovation could significantly benefit cardiac patients worldwide. Dr. Burg recently won a prestigious award at a leading cardiology conference, highlighting the potential impact of her work. She plans to conduct clinical trials in humans by 2027, marking a significant step forward in the development of this technology.
Product Stage
growth-positive
Symbiosis Wins TCT 2024 Shark Tank Innovation Competition
Symbiosis has won the TCT 2024 Shark Tank Innovation Competition for its adjustable transcatheter mitral valve replacement (TMVR) system, ValSync. The competition was held during the Transcatheter Cardiovascular Therapeutics symposium in Washington, DC. ValSync is designed to adapt to complex anatomies, offering potential benefits such as wider patient eligibility and superior safety. Symbiosis is currently in preclinical studies and plans to begin human testing in 2026. The company received a $200,000 award from the Jon DeHaan Foundation, which supports advancements in cardiac medicine. The recognition highlights Symbiosis innovation and potential to disrupt the cardiovascular field.
Product StageInvestment
growth-positive
Symbiosis Welcomes Prof. Marc Gillinov to Advisory Board
Symbiosis has announced the addition of Dr. Marc Gillinov to its Advisory Board. Dr. Gillinov is a renowned expert in mitral valve repair and robotic mitral valve surgery, currently serving as the Chair of the Department of Thoracic and Cardiovascular Surgery at Cleveland Clinic. His extensive experience and contributions to the field, including over 500 publications and educational videos, are expected to bring significant expertise to Symbiosis. This move is seen as a positive development for Symbiosis, potentially enhancing its capabilities and reputation in the cardiovascular domain.
growth-positive
Robert Schwartz Interviews Dr. Shira Burg at TCT Shark Tank 2024
Shira Burg, the Founder and CEO of Symbiosis, was awarded the Jon DeHaan Award at the TCT Shark Tank 2024. The interview highlights Shiras transition from veterinary medicine to human cardiology, emphasizing her dedication to treating structural heart disease. This recognition at a prestigious event like TCT Shark Tank is a significant milestone for Symbiosis, indicating a positive impact on the companys reputation and potential growth in the cardiology field.
growth-positive
ValSync Development Featured in JACC
The article discusses the ValSync device, a next-generation solution for Transcatheter Mitral Valve Replacement (TMVR), co-authored by Dr. Shira Burg and Dr. Yulia Cladco in JACC: Basic to Translational Science. ValSync addresses challenges in TMVR caused by irregular anatomy and mitral annular calcifications. Its design features inflatable balloons that adapt to individual patient anatomy, providing stability and reducing risks such as paravalvular leaks and left ventricular outflow tract obstruction. This innovation could broaden patient eligibility and simplify the TMVR procedure. Initial animal trials have shown promising results, with potential first-in-human trials expected in 2026.
Product Stage
growth-positive
TCT 2024: Symbiosis wins Shark Tank innovation prize
Symbiosis, a developer of the Valsync adjustable transcatheter mitral valve replacement (TMVR) system, won the Shark Tank innovation prize at the 2024 Transcatheter Cardiovascular Therapeutics (TCT) conference. The Valsync system, designed for mitral valve replacement, features a unique balloon system adaptable to various valve shapes. Symbiosis is currently conducting a chronic animal study and plans to start a first-in-human trial by late 2026. The company has strengthened its advisory board with Stanton Rowe, former chief scientific officer at Edwards Lifesciences. The TCT Shark Tank Innovation Competition, in partnership with the Jon DeHaan Foundation, awarded Symbiosis a $200,000 prize to support its innovative cardiovascular solutions.
Product StagePartners
growth-positive
Breaking the MedTech Glass Ceiling
Symbiosis CM, a startup founded by Dr. Shira Burg and Varda Badet, is developing a medical device that personalizes treatment of heart disease. The company was born out of a semester-long workshop for women at Tel Aviv University’s Entrepreneurship Center. The startup has raised $1.9M and won a number of competitions and grants. The device being developed by Symbiosis CM allows for real-time valve adjustment per an individual’s heart structure and minimally invasive procedures to treat heart disease. The startup team already has a working prototype in preclinical trials. The company recently brought on a new CEO, Amir Weisberg, who has 35 years of entrepreneurial experience.
InvestmentManagement Changes
growth-positive
Symbiosis C.M’s mission to help our hearts
Dr. Shira Burg, CEO & Founder of Symbiosis C.M., a veterinarian with vast experience in veterinary cardiology, has developed a personalized approach for heart valve replacement for humans and animals. This comes as a response to the challenges faced by patients suffering from mitral valve insufficiency, a cardiac disease common in dogs. According to Symbiosis C.M., about 65-70% of patients with moderate-severe secondary mitral valve insufficiency are ineligible for mitral valve replacement. If left untreated, these patients have a 50% mortality rate within five years and over 90% rehospitalizations due to heart failure.
Customers
growth-positive
זוכי תחרות קולר ה-6: ייעול משלוחים, גידול חלבון בצמחים והתאמה אישית של ציוד רפואי
Three startups, Pierate.io, Symbiosis C.M, and PoLoPo, have emerged as winners in a startup competition organized by the Coller Faculty of Management at Tel Aviv University. The competition attracted about 110 startups and projects in three tracks, with 13 of them making it to the final stage. Pierate.io, an online company, won the biggest prize of $200,000. The company has developed a unique technological solution for international shipping companies that optimizes the process of generating price quotes. Symbiosis C.M and PoLoPo each won an investment of $100,000.
Investment
growth-positive
יזמיות שלנו זכו ב-100,000$ ב-Coller Startup Competition
Symbiosis C.M, a startup founded by Dr. Shira Borg and Vered Badt, has won the Coller Startup Competition, receiving a prize of $100,000. The startup is developing a solution for material insufficiency in the heart, the most common heart disease. The idea was inspired by Borgs experience as a veterinarian, seeing many dogs suffering from the problem. The startup was established as part of the Entrepreneurship on Campus program and has already raised significant investment.
Investment
Symbiosis C.M. Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 16 |
| Team members | 4 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 9 classification IDs that could be used for matching.
Symbiosis C.M. Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 80/100 |
| Missing | sector, video or image, markets, not claimed |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 516348679 |
| Phone | 0532824436 |
| Creator | Shira Burg |
| Creator email | shira.burg@symbiosis-cm.com |
| Last update | 2024-06-16T00:00:00.000Z |
| Created | 2024-06-16T00:00:00.000Z |
| Claimed | Yes |